These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced that Laura J. Esserman, MD ...
Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback